![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 23, 2011 3:05:28 PM
"Our agreement with Gulf Coast Pharmaceuticals provides InoLife Technologies, Inc. with a vital sales channel and vast product outreach to our key customers, including consumers, hospitals, general practitioners and cardiologists," said Gary Berthold, President, CEO of InoLife Technologies, Inc. "Gulf Coast will provide our company with a large-scale distribution warehouse and a North American-wide sales force, allowing us to accelerate market penetration of our DNA-based product line."
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM